Showing results (11-20 of 204) with videos related to
Sort By:
Pageof 21
Biochemistry|October 3, 2013
Drug rescue distinguishes between different structural models of human P-glycoproteinTip W Loo, David M ClarkeBiochemical Pharmacology|April 4, 2017
Corrector VX-809 promotes interactions between cytoplasmic loop one and the first nucleotide-binding domain of CFTRTip W Loo, David M ClarkeBiochemistry|May 10, 2016
Drugs Modulate Interactions between the First Nucleotide-Binding Domain and the Fourth Cytoplasmic Loop of Human P-GlycoproteinTip W Loo, David M ClarkeThe Journal of Biological Chemistry|September 12, 2002
Location of the rhodamine-binding site in the human multidrug resistance P-glycoproteinTip W Loo, David M ClarkeBiochemical and Biophysical Research Communications|March 2, 2005
Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?Tip W Loo, David M ClarkeBiochemical and Biophysical Research Communications|May 24, 2017
Thiol-reactive drug substrates of human P-glycoprotein label the same sites to activate ATPase activity in membranes or dodecyl maltoside detergent micellesTip W Loo, David M ClarkeMethods in Molecular Biology (Clifton, N.J.)|May 20, 2011
Repair of CFTR folding defects with correctors that function as pharmacological chaperonesTip W Loo, David M ClarkeThe Journal of Biological Chemistry|October 29, 2015
Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoproteinTip W Loo, David M ClarkeBiochemical Pharmacology|December 3, 2014
Tariquidar inhibits P-glycoprotein drug efflux but activates ATPase activity by blocking transition to an open conformationTip W Loo, David M ClarkeBiochemical Pharmacology|January 14, 2014
The cystic fibrosis V232D mutation inhibits CFTR maturation by disrupting a hydrophobic pocket rather than formation of aberrant interhelical hydrogen bondsTip W Loo, David M ClarkePageof 21